Troriluzole + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive-Compulsive Disorder
Conditions
Obsessive-Compulsive Disorder
Trial Timeline
Dec 19, 2017 → Dec 8, 2025
NCT ID
NCT03299166About Troriluzole + Placebo
Troriluzole + Placebo is a phase 2/3 stage product being developed by Biohaven for Obsessive-Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03299166. Target conditions include Obsessive-Compulsive Disorder.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04693351 | Phase 3 | Completed |
| NCT04641143 | Phase 3 | Completed |
| NCT03701399 | Phase 3 | Active |
| NCT03829241 | Phase 3 | Completed |
| NCT03299166 | Phase 2/3 | Completed |
Competing Products
8 competing products in Obsessive-Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |